Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 28, 2026

Coca-Cola Reports First Quarter 2026 Results and Updates Full Year Guidance

View original at finance.yahoo.com
“Cash flow: Cash flow from operations and free cash flow (non-GAAP) were $2.0 billion and $1.8 billion, respectively.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • In the Philippines, single-serve Coca-Cola Zero Sugar packs grew double digits and delivered away-from-home volume growth

    60% confidence
  • EPS grew 18% to $0.91 in Q1 2026, with a 6-point currency tailwind; comparable EPS grew 18% to $0.86 with a 3-point currency tailwind

    60% confidence
  • Operating margin was 35.0% versus 32.9% in the prior year; comparable operating margin was 34.5% versus 33.8% in the prior year

    60% confidence
  • Cash flow from operations was $2.0 billion and free cash flow was $1.8 billion in Q1 2026

    60% confidence
  • By leveraging key consumption occasions and local insights, the company increased weekly drinkers and gained value share globally during Q1 2026

    60% confidence
  • Coca-Cola set a Guinness World Record in Egypt for the most community meals served in one hour during Ramadan

    60% confidence
  • In North America, mini-can volume grew high single digits following the launch of single-serve mini-cans in convenience retail stores

    60% confidence
  • Operating income grew 19%; comparable currency neutral operating income grew 12% in Q1 2026

    60% confidence
  • Net revenues grew 12% to $12.5 billion in Q1 2026, and organic revenues grew 10%, driven by an 8% increase in concentrate sales and 2% growth in price/mix

    60% confidence
  • Sprite delivered double-digit volume growth in Brazil, supported by brand-led activations tied to Carnival and summer festivals

    60% confidence
  • Coca-Cola had a strong start to 2026 with performance reflecting unwavering focus on staying close to the consumer, executing locally and managing complexity

    60% confidence
  • Concentrate sales were 5 points ahead of unit case volume in Q1 2026, primarily due to six additional days in the quarter

    60% confidence
  • Global unit case volume grew 3% in Q1 2026

    60% confidence
  • The company gained value share in total non-alcoholic ready-to-drink beverages in Q1 2026

    60% confidence
  • Comparable operating margin expansion was driven by organic revenue growth and lower operating expenses, partially offset by higher input costs and increased marketing investments

    60% confidence

Data points we hold from this source

The Coca-Cola Company · concentrate sales growth8 percent
The Coca-Cola Company · operating income growth19 percent
The Coca-Cola Company · free cash flow1.8 USD
The Coca-Cola Company · comparable eps0.86 USD
The Coca-Cola Company · comparable currency neutral operating income growth12 percent
The Coca-Cola Company · margin35.0 percent
The Coca-Cola Company · unit case volume growth3 percent
The Coca-Cola Company · comparable operating margin34.5 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Coca-Cola Reports First Quarter 2026 Results and Updates Full Year Guidance — Source | Via News | ViaNews Market